Stealth BioTherapeutics Announces Mito Assist™ Patient Support Program and Specialty Pharmacy Partnership with AnovoRx to Distribute FORZINITY™(elamipretide) injection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
Source: PRnewswire
Launch of Mito Assist™ Program: Stealth BioTherapeutics has introduced the Mito Assist™ Patient Support Program to facilitate access to FORZINITY™ (elamipretide) injection, the first FDA-approved treatment for Barth syndrome, aimed at improving muscle strength in patients weighing at least 30 kg.
Partnership with AnovoRx: The company has partnered with AnovoRx Specialty Pharmacy to assist patients and caregivers with insurance navigation, co-pay assistance, and training for at-home injections, ensuring a smooth transition to commercial therapy for eligible patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
